Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study

Table 1 Age, menopausal stage, tumor characteristics and treatment

	Premenopausal^a	Postmenopausal^a	All
Number	13	20	33
Mean age at baseline	46.9 (36–54)	58.4 (50–71)	53.8 (36–71)
ER status
Positive	12	15	27
Negative	1	5	6
Tumor size (cm)
0.1–2.0	10	10	20
2.1–5.0	2	10	12
> 5.0	1	0	1
Histological grade
I	3	1	4
II	4	7	11
III	6	10	16
Unknown	0	2	2
HER 2 status
Normal	9	17	26
Overexpression	4	3	7
LN involvement
No	5	11	16
Yes	8 (1, 11)	9 (1, 2)	17
Laterality
Right	6	11	17
Left	6	9	15
Bilateral	1	0	1
Pathology
IDC	9	17	26
ILC	3	1	4
Other	1	2	3
Proliferation grade
< 35	7	8	15
35–70	5	9	14
> 70	1	2	3
Unknown	0	1	1
Treatment
Chemotherapy
Epirubicin	13	20	33
Cyclophosphamide	13	20	33
Docetaxel	4	4	8
Paclitaxel	9	16	25
Supplementary adjuvant treatment
Letrozole	0	12^b	12
Tamoxifen	9^b	1^c	10
Trastuzumab	1	1	2
Tamoxifen + trastuzumab	3	0	3
Letrozole + trastuzumab	0	2	2
Only chemotherapy	0	4	4

Four women (50%) receiving EC/Doc were reduced in dose because of side effects. One of these women was premenopausal
11 women (44%) receiving EC/Pac were reduced in dose because of side effects. All of these women were postmenopausal
One of the women receiving Paclitaxel had received one cycle of docetaxel before continuing with two cycles of paclitaxel
ER estrogen receptor, HER human epidermal growth factor receptor, LN lymph node
^aMenopausal status defined as: (A) premenopausal: menostasis < 12 month; hysterectomy and age < 55 years; cyclic hormonal treatment and age < 55 years. (B) Postmenopausal: all other women than the premenopausal and all oophorectomized
^bTwo patients assigned for letrozole and one assigned for tamoxifen discontinued within the 1st year because of side effects
^cOne postmenopausal women switched from letrozole to tamoxifen within the 1st year because of side effects

ISSN: 1479-5876